期刊文献+

尤瑞克林治疗血管性痴呆的临床观察

Efficacy Observation of Urinary Kallidinogenase in the Treatment of Vascular Dementia
原文传递
导出
摘要 目的:观察尤瑞克林治疗血管性痴呆的临床效果。方法:将76名血管性痴呆患者随机均分为治疗组与对照组,治疗组给予尤瑞克林注射液治疗,对照组给予银杏叶注射液治疗,2组疗程均为14d。2组分别于治疗前、后检测简易智能状态测量表(MMSE)、日常生活能力评定量表(ADL)评分及血液流变学指标。结果:治疗组患者MMSE、ADL评分及血液流变学指标改善情况显著优于治疗前及对照组(P<0.05)。2组均未见明显不良反应发生。结论:尤瑞克林治疗血管性痴呆具有一定的治疗作用,疗效优于银杏叶注射液。 OBJECTIVE: To investigate the effect of urinary kallidinogenase in the treatment of vascular dementia (VD). METHODS: 76 cases of VD were randomized into therapy group and control group. Therapy group was treated with urinary kallidi- nogenase injection, and control group was treated with Ginkgo leaf injection for 14 days. The changes of MMSE and ADL score and hemorheology indexes were observed before and after treatment. RESULTS: The score of MMSE and ADL and hemorheology indexes in therapy group were significantly improved, compared with control group (P〈0.05). No obvious adverse drug reaction was found. CONCLUSION: Urinary kallidinogenase has some therapeutic effect on VD, and the efficacy is better than Ginkgo leaf injection.
作者 李楠
出处 《中国药房》 CAS CSCD 2012年第36期3421-3423,共3页 China Pharmacy
关键词 尤瑞克林 血管性痴呆 银杏叶注射液 Urinary kallidinogenase Vascular dementia Ginkgo leaf injection
  • 相关文献

参考文献11

  • 1Robert M, Friedlander MD. Arteriovenous malformations of the brain[J]. NEngl, 2007,356(26) : 2 704.
  • 2Weinmann S, Roll S, Schwarzbach C, et al. Effects of ginkgo biloba in dementia: systematic review and me- ta-analysis[J]. BMC Geriatr , 2010,10:14.
  • 3王君森,上官纪勇.银杏叶注射液治疗血管性痴呆44例疗效观察[J].山东医药,2010,50(7):107-107. 被引量:9
  • 4Pohjasvaara T, Maintyla R, Ylikoski R, et al. Compari- son of different clinical crieria for the vascular cause of vascu; ardementia(ADDTC, DSM- 1II, DSM- IV, ICD-10, NINDS-ARIEN) [J]. Stroke, 2000,31 ( 12 ) : 2 952.
  • 5孙亚男,张本恕.盐酸多奈哌齐治疗血管性痴呆有效性及安全性临床分析[J].山东医药,2011,51(4):64-66. 被引量:30
  • 6王世君,祁玥.尤瑞克林治疗急性脑梗死40例临床观察[J].陕西医学杂志,2011,40(3):374-374. 被引量:6
  • 7贾建平,左秀美.血管性痴呆诊断与治疗[J].内科急危重症杂志,2007,13(1):1-3. 被引量:26
  • 8Emanueli C, Madeddu P. Angiogenesis therapy with hu- man tissue Kallikrein for the treatment of ischemic diseas- es[J]. Arch Mal CoeurVaiss, 2004,97 (6) : 679.
  • 9Xia CF, Yin H, Borlongan CV, et al. Kallikrein gene transfer protects against ischemic stroke bypromoting gli-alcellmigration and inhibiting apoptosis[J]. Hypertension, 2004,43(2) :452.
  • 10Ling L, Hou Q, Xing S, et al. Exogenous kallikrein en- hances neurogenesis and angiogenesis in the subventricu-lar zone and the peri-infarction region and improves neu- rological function after focal cortical infarction in hyper- tensive rats[J]. Brain Res, 2008,12 (6) : 89.

二级参考文献35

  • 1丁德云.新药临床研究之路——凯力康(注射用尤瑞克林)临床研究简介[J].中国处方药,2005,4(11):63-66. 被引量:43
  • 2屈志炜,苏丹,张丽英,吴俊芳,巫锦娣,王晓岩,谢永立.凯力康对大鼠局灶性脑缺血的实验研究[J].中国处方药,2005,4(11):73-75. 被引量:43
  • 3李欣吉,骆翔,王雪贞,刘潺潺,卜碧涛.尤瑞克林治疗急性脑梗死的临床观察[J].神经损伤与功能重建,2007,2(3):164-165. 被引量:24
  • 4Pohjasvaara T,Mantyla R,Ylikoski R,et al.Comparison of different clinical criteria for the vascular cause of vascular dementia(AD-DTC,DSM-Ⅲ,DSM-Ⅳ,ICD-10,NINDS-AIREN)[J].Stroke,2000,31(12):2952-2957.
  • 5Desmond DW,Moroney JT,Sano M,et al.Mortality in patients with dementia after ischemic stroke[J].Neurology,2002,59(4):537-543.
  • 6Ellis JM.Cholinesterase Inhibitors in the treatment of dementia[J].JAOA,2005,105(3):145-158.
  • 7Farlow MR.Use of Antidementia agents in vascular dementia:beyond Alzheimer disease[J].Mayo Clin Proc,2006,81(10):1350-1358.
  • 8Akaike A.Preclinical evidence of neuroprotection by cholinesterase inhibitors[J].Alzheimer Dis Assoc Disord,2006,20(2 suppl):S8-S11.
  • 9Romàn GC,Wilkinson DG,Doody RS,et al.Donepezil in vascular dementia:combined analysis of two large-scale clinical trials[J].Dement Geriatr Cogn Disord,2005,20(6):338-344.
  • 10王拥军.神经病学临床评定量表[M].北京:中国友谊出版公司,2005,6.

共引文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部